KAS
TVTX icon

Kemnay Advisory Services’s Travere Therapeutics TVTX Stock Holding History

Kemnay Advisory Services’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$22.4K Buy
+753
New +$22.5K ﹤0.01% 621

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Kemnay Advisory Services's TVTX Position: Q1 2026 in Review

Kemnay Advisory Services opened a new position in Travere Therapeutics (TVTX) in Q1 2026: 753 shares worth $22.4K. The stake represents ﹤0.01% of the portfolio and ranks #621 among its holdings.

260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Kemnay Advisory Services held 753 shares of Travere Therapeutics worth $22.4K as of Q1 2026.
  • Travere Therapeutics was a new Kemnay Advisory Services position in Q1 2026.
  • Travere Therapeutics made up ﹤0.01% of Kemnay Advisory Services's portfolio in Q1 2026, its #621 holding.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Kemnay Advisory Services's 13F filing for Q1 2026, filed 15 May 2026.